T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?

María-Victoria Mateos
Nature Reviews Clinical Oncology · Springer Nature · 2026-11-10 · DOI: 10.1038/s41571-026-01230-2

Аннотация

Nature Reviews Clinical Oncology, Published online: 10 November 2026; doi:10.1038/s41571-026-01230-2 The randomized phase II ImmunoPRISM trial has shown encouraging efficacy of the B cell maturation antigen-targeted bispecific T cell engager teclistamab in high-risk smouldering multiple myeloma, although several aspects constrain interpretation of the results. Herein, I discuss aspects that should be addressed in future research, such as patient selection, treatment duration, clinically relevant end points and adequate treatment in the control arm, to establish whether deep responses translate into durable prevention of progression with an acceptable benefit–risk profile.

Читать у издателя →

Похожие статьи